TCID50

ZeptoMetrix Launches PROtrol: Quality Control Material for the Lateral Flow Immunoassay Market

Retrieved on: 
Tuesday, May 16, 2023
COVID-19, TCID50, Infection, Patient, SARS-CoV-2, Vaccine

These third-party materials mimic a true clinical specimen and can be used to evaluate and monitor the performance of antigen-based assays, including lateral flow immunoassays for infectious diseases.

Key Points: 
  • These third-party materials mimic a true clinical specimen and can be used to evaluate and monitor the performance of antigen-based assays, including lateral flow immunoassays for infectious diseases.
  • PROtrol is the only whole organism reference material to provide complete testing data.
  • Each lot of product is supplied with the protein concentration and TCID50 value, which minimizes qualification testing.
  • More information on how to order the new PROtrol and additional ZeptoMetrix products can be found at: https://www.zeptometrix.com

Recce Pharmaceuticals Announces Preclinical SARS-CoV-2 Study Update

Retrieved on: 
Tuesday, October 18, 2022
Degenerative disease, FSE, TCID50, ASX, Gram-negative bacteria, Virus, Infection, Animal, Severe acute respiratory syndrome coronavirus 2, Recce, Human, Pew, Hepatitis, Inhalation, HIV, Administration, Company, RCE, Intention, Patent, Safety, Bacteria, GLOBE, CSIRO, GAIN, Ferret, Real-time, FDA, COVID-19, Synthetic, CRO, Vaccine, Pharmaceutical industry

SYDNEY, Australia, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q) (the Company), the Company developing a new class of synthetic anti-infectives, is pleased to provide an update from its preclinical studies evaluating RECCE® 327 (R327) against the SARS-CoV-2 virus. The studies were conducted by Viroclinics, an independent, third-party contract research organization (CRO) based in the Netherlands.

Key Points: 
  • RECCE 327 (R327) was shown to significantly reduce SARS-CoV-2 levels in hamsters, the gold-standard in COVID-19 preclinical animal models
    New patents lodged supporting anti-infective capability in Brazil, Canada, China, Israel, India and Vietnam
    SYDNEY, Australia, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q) (the Company), the Company developing a new class of synthetic anti-infectives, is pleased to provide an update from its preclinical studies evaluating RECCE 327 (R327) against the SARS-CoV-2 virus.
  • The data received from Viroclinics indicates the potential of R327s capabilities as a treatment for viral infections," said James Graham, Chief Executive Officer of Recce Pharmaceuticals.
  • Conducting our SARS-CoV-2 study in the Netherlands reaffirms the Companys intention to address the ongoing effects that Europe has experienced throughout the pandemic.
  • Considering the positive study results from the SARS-CoV-2 in-vivo hamster study at Viroclinics, the Company will consolidate its focus on anti-viral (COVID-19) studies overseas.

ASC Therapeutics Announces Podium and Poster Presentations of IND-Enabling Studies for ASC618, a Second-Generation Gene Therapy for Hemophilia A, at the 25th ASGCT Meeting, May 16-19, 2022 in Washington, D.C.

Retrieved on: 
Tuesday, May 17, 2022
Research, FDA, Genetics, Clinical Trials, Stem Cells, Biotechnology, Health, Pharmaceutical, Science, PM, TCID50, International Society, VIII, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, VP, Annual general meeting, Lists of diseases, Haemophilia, Doctor of Philosophy, European Medicines Agency, Patient, Poster, Unfolded protein response, Gene editing, Therapy, Thrombosis, Clinical trial, Immunotherapy, Society, ISTH, AM, Haemophilia A, Gene, DOI, FDA, IND, Allotransplantation, COMP, Toxicology, EMA, Program, Congress, Safety, Biology, Maple syrup urine disease, Cell, Committee, International Society on Thrombosis and Haemostasis, ASC, CEO, Pharmaceutical industry, Vaccine, Hemostasis, Mouse

These studies were included in a filing to the U.S. Food and Drug Administration (FDA) leading to IND clearance of ASC618 .

Key Points: 
  • These studies were included in a filing to the U.S. Food and Drug Administration (FDA) leading to IND clearance of ASC618 .
  • We are thrilled to bring a second-generation gene therapy treatment to patients with Hemophilia A.
  • Thousands of cell and gene therapy developers, including basic and clinical investigators represent the academic, regulatory, and biotechnology sectors.
  • Hemophilia A gene therapy: current and next-generation approaches, Expert Opinion on Biological Therapy 2022 Jan 6;1-17, DOI: 10.1080/14712598.2022.2002842
    View source version on businesswire.com: https://www.businesswire.com/news/home/20220516005908/en/

DiNAQOR Opens DiNAMIQS Subsidiary to Partner with Gene Therapy Companies Bringing New Treatments to Patients

Retrieved on: 
Monday, May 16, 2022
TCID50, Risk, GMP, Solution, Biomass, Automation, D, Desalting and buffer exchange, Research, ELISA, AAV, Biotechnology, Safety, Technology, Drug development, Therapy, Quality control, Ion exchange, CEO, Fine chemical, Pharmaceutical industry, Vaccine, Central Europe

ZURICH-SCHLIEREN, Switzerland, May 16, 2022 /PRNewswire/ -- DiNAQOR announced today the launch of DiNAQOR DiNAMIQS, a biomanufacturing subsidiary, that will accelerate development timelines and reduce costs and risk for genetic medicine companies bringing new treatments to market.

Key Points: 
  • DiNAQOR DiNAMIQS is based in the company's state-of-the-art, 1,200-square-meter (13,000 square feet) manufacturing facility in Bio-Technopark Schlieren-Zrich, the leading center for biotechnology companies in Central Europe.
  • "We look forward to partnering with the world's leading gene therapy companies," said Johannes Holzmeister, M.D., Chairman and CEO of DiNAQOR.
  • "There are always challenges in the development process, and DiNAQOR DiNAMIQS is ideally suited to meet and overcome them.
  • DiNAQOR DiNAMIQS provides a comprehensive range of manufacturing services, process development, quality control and analytics solutions to support and accelerate gene therapy projects.

ViQi, Inc. awarded a National Science Foundation grant SBIR Phase II: Machine learning for Rapid Automated Viral Infectivity Assays

Retrieved on: 
Thursday, April 21, 2022
Unitus Seed Fund, FFA, Calibration, National Science Foundation, DNA, Adenoviridae, SBIR, NSF, Research, R, Science, Infection, CA, RNA, Small Business Innovation Research, Machine learning, Education, Environmental monitoring, Cell, Engineering, Virology, TCID50, Technology, Vaccine, Plaque, Intelligence, Immortalised cell line, Expansion microscopy, Antibody, HIV, Virus, Time, Pharmaceutical industry

SANTA BARBARA, Calif., April 21, 2022 /PRNewswire-PRWeb/ -- Development of viral vaccines and antiviral drugs requires viral infectivity assays, however, the incubation periods of plaque and TCID50 assays can be as long as 14 days, and the alternatives like focus forming assay (FFA) require antibodies and extensive sample preparation or developing GFP-labeled viruses which is not always possible or desirable. This automated viral infectivity assay is based on brightfield microscopy, not requiring any stains or labels. A one time calibration of the machine learning model on a specific combination of virus, cell line, and imager is required to detect phenotypic changes associated with early stages of active virus infection in cells before being humanly visible. Detection can be done within hours (same-day) for fast-acting viruses or in as long as two days for viruses that take up to two weeks to develop infections detectable by conventional means. Not only will this assay significantly reduce the turn-around time and processing steps required, it can also be completely automated with conventional equipment used for high-content screening.

Key Points: 
  • ViQi Inc, a California image analysis company specializing in enabling the use of artificial intelligence in the scientific discovery process, announced today the confirmation of Phase II National Science Foundation (NSF) grant to further optimize their cloud analysis solution applying machine learning to automate viral infectivity assays, significantly reducing the time required for these assays.
  • This automated viral infectivity assay is based on brightfield microscopy, not requiring any stains or labels.
  • Not only will this assay significantly reduce the turn-around time and processing steps required, it can also be completely automated with conventional equipment used for high-content screening.
  • America's Seed Fund powered by the National Science Foundation (NSF) awards $200 million annually to startups and small businesses, transforming scientific discovery into products and services with commercial and societal impact.

InDevR Launches ArrayMax Mixer for Even Faster VaxArray Assay Times

Retrieved on: 
Tuesday, November 16, 2021
Coronavirus, ELISA, SRID, Serology, Polio, CTO, Vaccine, GLOBE, TCID50, Time

BOULDER, Colo., Nov. 16, 2021 (GLOBE NEWSWIRE) -- InDevR, Inc., a life science tools company providing powerful analytical technologies to support the development and production of vaccines and biotherapeutics, announced commercial availability of its new ArrayMaxTM Mixer to provide significantly reduced assay times for its VaxArray Portfolio of immunoassay kits.

Key Points: 
  • BOULDER, Colo., Nov. 16, 2021 (GLOBE NEWSWIRE) -- InDevR, Inc., a life science tools company providing powerful analytical technologies to support the development and production of vaccines and biotherapeutics, announced commercial availability of its new ArrayMaxTM Mixer to provide significantly reduced assay times for its VaxArray Portfolio of immunoassay kits.
  • Current VaxArray Assays include kits for influenza, coronavirus, measles/rubella, and polio, and provide vaccine manufacturers faster characterization of identity, quantity, and stability parameters during manufacture and release of vaccine products.The ArrayMax Mixer significantly improves mixing over static incubation or traditional orbital shakers during assay execution using either antibody or antigen samples.In internal validation studies comparing ArrayMax to original VaxArray protocols, similar or improved analytical performance was obtained using new ArrayMax-executed VaxArray protocols and up to an 85% reduction of time to result was obtained.
  • In a small 6"x 6" footprint, this convenient new tool provides the possibility to generate VaxArray results in a fraction of the time compared to traditional ELISA, providing a total assay time of less than onehour for currently available VaxArray Kits.
  • Erica Dawson, CTO of InDevR, noted, "Our VaxArray Assay Kits already provide significant advantages over outdated, laborious, and error prone techniques such as SRID, TCID50, and ELISAs.This further reduction in total assay time for the VaxArray Kits will benefit any vaccine development or manufacturer in bioprocess development, optimization and monitoring, as well as vaccine release testing.We are excited to continue empowering vaccine producers by further expanding our portfolio."